Table 1.
Study acronyms and their respective clinical trial full names (in alphabetical order)
| Acronyms | Clinical trial full names |
|---|---|
| ACE | Abciximab and Carbostent Evaluation |
| ACUITY | Acute Catheterization and Urgent Intervention Triage Strategy |
| ADMIRAL | Abciximab Before Direct angioplasty and stenting in Myocardial Infarction Regarding Acute and Long-term Follow-up |
| ARMYDA-2 | The Antiplatelet Therapy for Reduction of Myocardial Damage during Angioplasty – 2nd edition |
| ASPIRE | Arixtra Study in Percutaneous Coronary Intervention |
| ATOLL | Acute STEMI Treated With Primary Angioplasty and Intravenous Lovenox or Unfractionated Heparin |
| BRIDGE | Maintenance of Platelet inhibition with cangreLor after discontinuation of Thienopyridines in Patients Undergoing surgery |
| CHAMPION-PCI | Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition-percutaneous Coronary Intervention |
| CHAMPION-PLATFORM | Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (Platform) |
| CREDO | Reduction of Events during Observation |
| CURRENT/OASIS-7 | Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for Interventions |
| DISPERSE | Dose Confirmation Study Assessing Anti-platelet Effects |
| EPIC | Evaluation of 7E3 for the Prevention of Ischemic Complications |
| ESPRIT | Enhanced Suppression of the Platelet IIb/IIa Receptor with Integrilin Therapy |
| HORIZONS-AMI | Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction |
| IMPACT-II | Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis |
| ISAR | Intracoronary Stenting and Antithrombotic Regimen |
| ISAR-CHOICE | Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect |
| ISAR-REACT | Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment |
| MATE | A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy |
| MULTISTRATEGY | MULTIcenter Evaluation of Single High-dose Bolus Tirofiban versus Abciximab with Sirolimus Eluting STEnt or Bare Metal Stent in Acute Myocardial Infacrtion |
| OASIS-5 | The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes |
| OASIS-6 | The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes |
| ON-TIME-2 | Ongoing Tirofiban in Myocardial Infaction Evaluation 2 |
| PCI-CURE | Percutaneous coronary intervention-Clopidogrel in Unstable angina to prevent Recurrent Events |
| PLATO | A Study of Platelet Inhibition and Patient Outcomes |
| REPLACE-2 | Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events-2 |
| SYNERGY | Safety and efficacy of enoxaparin versus unfractionated heparin in patients with non-ST segment elevation acute coronary syndromes who receive tirofiban and aspirin |
| TACTICS-TIMI 18 | Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction 18 |
| TIMI IIIB | Thrombolysis in Myocardial Ischemia |
| TRILOGY | A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/ Non-ST-Elevation Myocardial Infarction Who Are Medically Managed |
| TRITON-TIMI 38 | Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction |
| VANQWISH | Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital |